|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATXN7L1 |
Gene summary for ATXN7L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATXN7L1 | Gene ID | 222255 |
| Gene name | ataxin 7 like 1 | |
| Gene Alias | ATXN7L4 | |
| Cytomap | 7q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q9BTQ8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 222255 | ATXN7L1 | CCI_1 | Human | Cervix | CC | 2.36e-22 | 1.21e+00 | 0.528 |
| 222255 | ATXN7L1 | CCI_2 | Human | Cervix | CC | 4.31e-05 | 5.98e-01 | 0.5249 |
| 222255 | ATXN7L1 | CCI_3 | Human | Cervix | CC | 2.81e-24 | 9.64e-01 | 0.516 |
| 222255 | ATXN7L1 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.09e-10 | 6.65e-01 | -0.1954 |
| 222255 | ATXN7L1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.54e-02 | 6.16e-01 | 0.0112 |
| 222255 | ATXN7L1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.35e-08 | -3.73e-01 | 0.294 |
| 222255 | ATXN7L1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.47e-03 | 5.47e-01 | 0.281 |
| 222255 | ATXN7L1 | A001-C-207 | Human | Colorectum | FAP | 2.40e-03 | -1.69e-01 | 0.1278 |
| 222255 | ATXN7L1 | A015-C-203 | Human | Colorectum | FAP | 4.41e-34 | -5.52e-01 | -0.1294 |
| 222255 | ATXN7L1 | A015-C-204 | Human | Colorectum | FAP | 2.14e-14 | -5.50e-01 | -0.0228 |
| 222255 | ATXN7L1 | A014-C-040 | Human | Colorectum | FAP | 1.95e-05 | -3.91e-01 | -0.1184 |
| 222255 | ATXN7L1 | A002-C-201 | Human | Colorectum | FAP | 2.68e-17 | -3.47e-01 | 0.0324 |
| 222255 | ATXN7L1 | A002-C-203 | Human | Colorectum | FAP | 1.18e-05 | 1.86e-01 | 0.2786 |
| 222255 | ATXN7L1 | A001-C-119 | Human | Colorectum | FAP | 3.62e-08 | -4.41e-01 | -0.1557 |
| 222255 | ATXN7L1 | A001-C-108 | Human | Colorectum | FAP | 2.83e-16 | -2.98e-01 | -0.0272 |
| 222255 | ATXN7L1 | A002-C-205 | Human | Colorectum | FAP | 7.27e-24 | -2.82e-01 | -0.1236 |
| 222255 | ATXN7L1 | A001-C-104 | Human | Colorectum | FAP | 2.37e-03 | -2.21e-01 | 0.0184 |
| 222255 | ATXN7L1 | A015-C-005 | Human | Colorectum | FAP | 2.24e-02 | -1.54e-01 | -0.0336 |
| 222255 | ATXN7L1 | A015-C-006 | Human | Colorectum | FAP | 2.42e-18 | -5.72e-01 | -0.0994 |
| 222255 | ATXN7L1 | A015-C-106 | Human | Colorectum | FAP | 3.71e-12 | -3.31e-01 | -0.0511 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATXN7L1 | SNV | Missense_Mutation | c.915N>C | p.Lys305Asn | p.K305N | Q9ULK2 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ATXN7L1 | SNV | Missense_Mutation | rs533762062 | c.692N>T | p.Ser231Leu | p.S231L | Q9ULK2 | protein_coding | tolerated(0.17) | benign(0) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATXN7L1 | SNV | Missense_Mutation | c.1757N>T | p.His586Leu | p.H586L | Q9ULK2 | protein_coding | tolerated(0.57) | benign(0.025) | TCGA-E2-A14T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ATXN7L1 | insertion | Frame_Shift_Ins | novel | c.111_112insTGCTTGCATAGTTTTTTGGGTACCTATCTGGGCCAGGTAGATGGAA | p.Ser38CysfsTer59 | p.S38Cfs*59 | Q9ULK2 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| ATXN7L1 | deletion | Frame_Shift_Del | c.220delA | p.Ser74AlafsTer5 | p.S74Afs*5 | Q9ULK2 | protein_coding | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |||
| ATXN7L1 | deletion | Frame_Shift_Del | novel | c.1793delN | p.Phe598SerfsTer83 | p.F598Sfs*83 | Q9ULK2 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ATXN7L1 | deletion | Frame_Shift_Del | novel | c.1271delN | p.Pro424HisfsTer29 | p.P424Hfs*29 | Q9ULK2 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ATXN7L1 | deletion | Frame_Shift_Del | novel | c.955delN | p.Leu319Ter | p.L319* | Q9ULK2 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ATXN7L1 | SNV | Missense_Mutation | c.2326G>A | p.Glu776Lys | p.E776K | Q9ULK2 | protein_coding | tolerated(0.18) | benign(0.202) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ATXN7L1 | SNV | Missense_Mutation | rs367798315 | c.2180C>T | p.Ala727Val | p.A727V | Q9ULK2 | protein_coding | tolerated(0.1) | benign(0) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |